'Milestone' study shows drug may halve cancer deaths and cut heart attack risks

An "exciting" new study has revealed a drug that could help reduce the risk of heart attacks and cut cancer deaths.

More than 10,000 patients took part in a trial using the anti-inflammatory Canakinumab, the results of which were presented at the European Society of Cardiology meeting in Barcelona, Spain.